As Low As $0
Out of Pocket
co-pay-caret
XEOMIN® - Important Safety Information

Adults With Upper Limb Spasticity

Disease
Overview
Clinical
Trial
Efficacy Safety Dosing

Demonstrated Safety in the Adults With Upper Limb Spasticity

In 2 clinical trials with total doses of 400 units, most patients experienced mild to moderate adverse reactions1,2

Adverse reactions to XEOMIN

References

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.
  2. Elovic EP, Munin MC, Kanovsky P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. Muscle Nerve. 2016;53(3):415-21.